0 43

Cited 0 times in

Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer

DC Field Value Language
dc.contributor.author임선민-
dc.date.accessioned2022-11-24T00:42:22Z-
dc.date.available2022-11-24T00:42:22Z-
dc.date.issued2021-05-
dc.identifier.issn1424-8247-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/190920-
dc.description.abstractAntibiotic-induced dysbiosis may affect the efficacy of immune checkpoint inhibitors. We investigated the impact of antibiotics on the clinical outcomes of nivolumab in patients with non-small cell lung cancer (NSCLC). Patients who received nivolumab for NSCLC between July 2015 and June 2018 and who were followed up until June 2020 were included in a retrospective cohort analysis. Of 140 eligible patients, 70 were on antibiotics. Overall survival (OS) was shorter in patients on antibiotics (ABX) compared to those not on antibiotics (NoABX) (p = 0.014). OS was negatively associated with piperacillin/tazobactam (PTZ) (HR = 3.31, 95% CI: 1.77-6.18), days of therapy (DOT) ≥ 2 weeks (HR = 2.56, 95% CI: 1.30-5.22) and DOT of PTZ. The defined daily dose (DDD) in PTZ (r = 0.27) and glycopeptides (r = 0.21) showed weak correlations with mortality. There was no difference in progression-free survival (PFS) between ABX and NoABX; however, PFS was negatively associated with the antibiotic class PTZ and DOT of PTZ. Therefore, the use of a broad-spectrum antibiotic, such as PTZ, the long-term use of antibiotics more than 2 weeks in total and the large amount of defined daily dose of specific antibiotics were associated with decreased survival in patients receiving nivolumab for NSCLC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfPHARMACEUTICALS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleBroad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMin Jung Geum-
dc.contributor.googleauthorChungsoo Kim-
dc.contributor.googleauthorJi Eun Kang-
dc.contributor.googleauthorJae Hee Choi-
dc.contributor.googleauthorJae Song Kim-
dc.contributor.googleauthorEun Sun Son-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorSandy Jeong Rhie-
dc.identifier.doi10.3390/ph14050445-
dc.contributor.localIdA03369-
dc.relation.journalcodeJ04088-
dc.identifier.pmid34066877-
dc.subject.keywordantibiotic-induced dysbiosis-
dc.subject.keyworddays of therapy-
dc.subject.keyworddefined daily dose-
dc.subject.keywordnivolumab-
dc.subject.keywordnon-small cell lung cancer-
dc.subject.keywordoverall survival-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.affiliatedAuthor임선민-
dc.citation.volume14-
dc.citation.number5-
dc.citation.startPage445-
dc.identifier.bibliographicCitationPHARMACEUTICALS, Vol.14(5) : 445, 2021-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.